Client of a consultant lobbyist
Apotex Inc.
- Meetings this Parliament
- 4
- With MPs
- 0
- Since Nov 2021
- 13
- Active registrations
- 1
Most recent reported meeting: Aug 6, 2025.
Lobbying by Apotex Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
Consultant In effect since Jun 11, 2026
Consultant Dan Mader of Loyalist Public Affairs
Consultant lobbyists
-
Dan Mader
Former designated public office holder
Formerly Chief of Staff, Office of the Associate Minister of National Defence, Department of National Defence (2011–2012)
Formerly Chief of Staff, Office of the Minister of State (Seniors), Employment and Social Development Canada (2011–2011)
Formerly Chief of Staff, Minister's Office, Environment Canada (2010–2011)
Formerly Director of Policy, Office of the Government House Leader, House of Commons (2010–2011)
-
Dan Mader
Former designated public office holder
Formerly Chief of Staff, Office of the Associate Minister of National Defence, Department of National Defence (2011–2012)
Formerly Chief of Staff, Office of the Minister of State (Seniors), Employment and Social Development Canada (2011–2011)
Formerly Chief of Staff, Minister's Office, Environment Canada (2010–2011)
Formerly Director of Policy, Office of the Government House Leader, House of Commons (2010–2011)
-
Dan Mader
Former designated public office holder
Formerly Chief of Staff, Office of the Associate Minister of National Defence, Department of National Defence (2011–2012)
Formerly Chief of Staff, Office of the Minister of State (Seniors), Employment and Social Development Canada (2011–2011)
Formerly Chief of Staff, Minister's Office, Environment Canada (2010–2011)
Formerly Director of Policy, Office of the Government House Leader, House of Commons (2010–2011)
Institutions they may lobby: Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Housing, Infrastructure and Communities Canada (HICC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Safety Canada (PS), Public Services and Procurement Canada (PSPC), Transport Canada (TC)
What they're lobbying on (1)Hide details
- Working with the government on an open and inclusive regulatory regime for generic pharmaceuticals that continues to allow the industry to grow in Canada, and discuss with the government how Apotex can work with them to ensure the security and increase the self-sufficiency of Canada’s drug supply, how the government can help ensure access to international markets including by ensuring that company employees based abroad can travel to Canada, and how the government can utilize generic and biosimilar medications to make pharmacare and other drug programs more sustainable.
Registration 931213-371257-10. Look it up in the official Registry
Reported meetings
Spreadsheet-
Reported by Dan Mader · Consultant
- Neeraj Bhalla · Director of Stakeholder Relations, Global Affairs Canada (GAC)
Working with the government on an open and inclusive regulatory regime for generic pharmaceuticals that continues to allow the industry to grow in Canada, and discuss with the government how Apotex can work with them to ensure the security and increase the self-sufficiency of Canada’s drug supply, how the government can help ensure access to international markets including by ensuring that company employees based abroad can travel to Canada, and how the government can utilize generic and biosimilar medications to make pharmacare and other drug programs more sustainable. Read more
-
Reported by Dan Mader · Consultant
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
- Jessica Fullerton · Senior Policy Asvisor, Finance Canada (FIN)
Working with the government on an open and inclusive regulatory regime for generic pharmaceuticals that continues to allow the industry to grow in Canada, and discuss with the government how Apotex can work with them to ensure the security and increase the self-sufficiency of Canada’s drug supply, how the government can help ensure access to international markets including by ensuring that company employees based abroad can travel to Canada, and how the government can utilize generic and biosimilar medications to make pharmacare and other drug programs more sustainable. Read more
-
Reported by Dan Mader · Consultant
- Shahad Khalladi · Senior Policy Advisor, Health Canada (HC)
Working with the government on an open and inclusive regulatory regime for generic pharmaceuticals that continues to allow the industry to grow in Canada, and discuss with the government how Apotex can work with them to ensure the security and increase the self-sufficiency of Canada’s drug supply, how the government can help ensure access to international markets including by ensuring that company employees based abroad can travel to Canada, and how the government can utilize generic and biosimilar medications to make pharmacare and other drug programs more sustainable. Read more
-
Reported by Dan Mader · Consultant
- Miro Froehlich · Director of Policy, Intergovernmental Affairs Secretariat (IGA)
- Galen Richardson · Stakeholder Relations Advisor, Intergovernmental Affairs Secretariat (IGA)
Working with the government on an open and inclusive regulatory regime for generic pharmaceuticals that continues to allow the industry to grow in Canada, and discuss with the government how Apotex can work with them to ensure the security and increase the self-sufficiency of Canada’s drug supply, how the government can help ensure access to international markets including by ensuring that company employees based abroad can travel to Canada, and how the government can utilize generic and biosimilar medications to make pharmacare and other drug programs more sustainable. Read more
-
Reported by Dan Mader · Consultant
- Matthew O'Connell · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Stephanie Claxton · Director of Policy, Health Canada (HC)
- Roy Karam · Director of Operations, Health Canada (HC)
Working with the government on an open and inclusive regulatory regime for generic pharmaceuticals that continues to allow the industry to grow in Canada, and discuss with the government how Apotex can work with them to ensure the security and increase the self-sufficiency of Canada’s drug supply, how the government can help ensure access to international markets including by ensuring that company employees based abroad can travel to Canada, and how the government can utilize generic and biosimilar medications to make pharmacare and other drug programs more sustainable. Read more
-
Reported by Dan Mader · Consultant
- Jason Easton · Strategic Advisor Special Projects, Prime Minister's Office (PMO)
Working with the government on an open and inclusive regulatory regime for generic pharmaceuticals that continues to allow the industry to grow in Canada, and discuss with the government how Apotex can work with them to ensure the security and increase the self-sufficiency of Canada’s drug supply, how the government can help ensure access to international markets including by ensuring that company employees based abroad can travel to Canada, and how the government can utilize generic and biosimilar medications to make pharmacare and other drug programs more sustainable. Read more
-
Reported by Dan Mader · Consultant
- Jade Mallette · Director of Parliamentary Affairs, Health Canada (HC)
Health
-
Reported by Dan Mader · Consultant
- Jade Mallette · Director of Parliamentary Affairs, Health Canada (HC)
Health
-
Reported by Dan Mader · Consultant
- Harry Orbach-Miller · Policy Advisor and Senior Coordinator, Prime Minister's Office (PMO)
International Trade
-
Reported by Dan Mader · Consultant
- Jason Easton · Chief of Staff, Global Affairs Canada (GAC)
Economic DevelopmentInternational Trade
-
Reported by Dan Mader · Consultant
- Alan Kessel · Assistant Deputy Minister, Global Affairs Canada (GAC)
International Trade
-
Reported by Dan Mader · Consultant
- Jason Easton · Chief of Staff, Global Affairs Canada (GAC)
International Trade
-
Reported by Dan Mader · Consultant
- Melissa Lantsman · Member of Parliament
HealthIndustryScience and TechnologyTransportation
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.